GE MEDICAL SYSTEMS

The cancer biomarkers market is projected to grow from USD 19.07 Billion in 2024 to USD 55.17 Billion by 2031, driven by advancements in genomics and precision medicine. Biomarkers are crucial for early cancer detection, therapy response prediction, and disease monitoring, with applications in drug discovery, diagnostics, and personalized treatment. Key market segments include breast and lung cancer, genetic and protein biomarkers, and profiling technologies like NGS and liquid biopsy. Regulatory support, increased healthcare spending, and collaborative research are accelerating market growth.

The global Life Science Instrumentation market is projected to grow from $75.9B in 2023 to $104B by 2030, driven by technological innovations, personalized medicine, and high-throughput screening. Key players include Agilent Technologies, Becton Dickinson, and Bio-Rad Laboratories. The report provides comprehensive market analysis, regional insights, and company profiles.

The SPEC-AI Nigeria trial evaluated AI-guided ECG-based screening vs. clinical ECGs alone for identifying cardiomyopathy among pregnant/postpartum women in Nigeria, utilizing AI algorithms for ECG analysis. The trial, funded by Mayo Clinic and NIH, involved six hospitals, with participants aged 18-49, randomized to AI-guided screening or standard ECG, followed up to 12 months postpartum. The primary outcome was identification of LVEF < 50% by echocardiography, with secondary outcomes including AI model performance and effectiveness in identifying various LVEF levels.